Nassef Eman Mostafa, Elabd Hemmat Ahmed, Elzomor Hala Mohamed, El Nagger Basma Mohamed Mohamed Ali, Ibrahim Amira Shahin, Ibrahim Amal Hussein, Kotb Hend Gamal, Hassan Donia Ahmed, Abd ElAziz Rasha Elsayed Mohamed, Mohamed Eman El Sayed
Internal Medicine Department, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt.
Rheumatology and Rehabilitation Department, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt.
Open Access Rheumatol. 2022 Dec 9;14:291-299. doi: 10.2147/OARRR.S391494. eCollection 2022.
Rheumatoid arthritis (RA) is a common systemic inflammatory disease. Collagen triple helix repeat containing-1 (CTHRC1) is a unique gene product able to reduce collagen deposition. The present study aimed to assess CTHRC1 level in RA patients and to uncover its relation to clinical, laboratory and radiological findings.
The study included 60 adult RA patients. In addition, there were 60 control subjects who included patients with osteoarthritis (n = 20) and reactive arthritis (n = 20) and healthy controls (n = 20). Serum CTHRC1 levels were assessed by Enzyme-Linked Immunosorbent Assay (ELISA). Disease activity was calculated using the Disease Activity Score (DAS28-CRP). Radiological damage was evaluated using the Simple Erosion Narrowing Score (SENS).
There was significantly higher serum CTHRC1 levels in RA patients when compared to OA, ReA and control groups [median (IQR): 4.66 (1.68-11.7) versus 1.88 (1.14-2.94), 1.55 (0.98-3.15) and 1.14 (0.85-1.3) mg/dL, respectively, p < 0.001]. There was significantly higher CTHRC1 levels in patients with higher disease activity [median (IQR): 2.23 (1.4-4.73) versus 6.55 (4.66-12.0) mg/dL, p = 0.004]. Patients with higher SENS had significantly higher CTHRC1 [median (IQR): 1.99 (1.4-4.66) versus 9.75 (4.39-12.63) mg/dL, p < 0.001] and DAS28 [median (IQR): 4.25 (2.9-5.2) versus 5.4 (4.65-5.8), p = 0.01].
Serum CTHRC1 levels are related to disease severity and radiological affection in RA patients.
类风湿关节炎（RA）是一种常见的全身性炎症性疾病。含胶原蛋白三螺旋重复序列-1（CTHRC1）是一种能够减少胶原蛋白沉积的独特基因产物。本研究旨在评估RA患者的CTHRC1水平，并揭示其与临床、实验室及影像学检查结果的关系。
本研究纳入60例成年RA患者。此外，还有60例对照受试者，包括骨关节炎患者（n = 20）、反应性关节炎患者（n = 20）和健康对照者（n = 20）。采用酶联免疫吸附测定（ELISA）法评估血清CTHRC1水平。使用疾病活动评分（DAS28-CRP）计算疾病活动度。采用简易侵蚀狭窄评分（SENS）评估影像学损伤。
与骨关节炎、反应性关节炎和对照组相比，RA患者的血清CTHRC1水平显著更高[中位数（四分位间距）：分别为4.66（1.68 - 11.7）mg/dL、1.88（1.14 - 2.94）mg/dL、1.55（0.98 - 3.15）mg/dL和1.14（0.85 - 1.3）mg/dL，p < 0.001]。疾病活动度较高的患者CTHRC1水平显著更高[中位数（四分位间距）：2.23（1.4 - 4.73）mg/dL对6.55（4.66 - 12.0）mg/dL，p = 0.004]。SENS较高的患者CTHRC1水平显著更高[中位数（四分位间距）：1.99（1.4 - 4.66）mg/dL对9.75（4.39 - 12.63）mg/dL，p < 0.001]，DAS28也显著更高[中位数（四分位间距）：4.25（2.9 - 5.2）对5.4（4.65 - 5.8），p = 0.01]。
RA患者血清CTHRC1水平与疾病严重程度及影像学损害相关。
